June 5, 2018 — The U.S. Food and Drug Administration (FDA) has cleared the Biograph Vision, a new positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.
Molecular Imaging
Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.
-
-
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Laboratories’ (CNL) Nuclear Research and Test Establishment Operating License for the Chalk River Laboratories (CRL) site.
-
February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took steps to ensure a stable and secure supply of a critical radioactive imaging tracer used to detect potentially life-threatening diseases.
-
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and president-elect of the American Society of Nuclear Cardiology (ASNC), explained advances in PET and SPECT imaging and the learning curve involved in reading scans from the new CZT...
-
Randy Thompson, M.D., attending cardiologist, St. Luke’s Mid-America Heart Institute, Kansas City, explains protocols and what to consider when working with the newer generation CZT-SPECT camera systems for nuclear cardiology.
News | PET Imaging | July 17, 2018
July 17, 2018 — A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new...
Technology | Nuclear Imaging | July 16, 2018
July 16, 2018 — At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23...
IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.
68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.
News | PET Imaging | June 29, 2018
June 29, 2018 — In the battle against metastatic castrate-resistant...
Technology | PET Imaging | June 28, 2018
June 28, 2018 — At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in...
News | PET Imaging | June 25, 2018
June 25, 2018 — IMV, part of the Science and Medicine Group and a market research and business intelligence provider...
News | SPECT Imaging | June 21, 2018
June 21, 2018 — The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for...
Technology | PET-CT | June 21, 2018
June 21, 2018 — Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new...
News | Prostate Cancer | June 13, 2018
June 13, 2018 — A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine...
Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.
Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S. Food and Drug Administration (FDA) has cleared the Biograph Vision, a new...
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of...
News | Computed Tomography (CT) | May 21, 2018
May 21, 2018 — The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation...
Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea
News | PET Imaging | May 17, 2018
May 17, 2018 — A novel positron emission...
News | PET Imaging | May 11, 2018
May 11, 2018 — A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics Acquires Worldwide Rights to Investigational Radiohybrid PSMA-Targeted Agents
May 9, 2018 — Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a...
News | Radiopharmaceuticals and Tracers | May 03, 2018
May 3, 2018 — BWX Technologies Inc. signed a definitive agreement to acquire Sotera Health’s Nordion...
Cardiac MRI being performed at the DeBakey Heart Hospital.
Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland
News | PET Imaging | April 10, 2018
April 10, 2018 — Researchers have developed a new imaging agent that could help guide and assess treatments for...
